TR201909078T4 - Kimyasal bileşikler ve bunların kas kalitesinin iyileştirilmesine yönelik kullanımı. - Google Patents

Kimyasal bileşikler ve bunların kas kalitesinin iyileştirilmesine yönelik kullanımı. Download PDF

Info

Publication number
TR201909078T4
TR201909078T4 TR2019/09078T TR201909078T TR201909078T4 TR 201909078 T4 TR201909078 T4 TR 201909078T4 TR 2019/09078 T TR2019/09078 T TR 2019/09078T TR 201909078 T TR201909078 T TR 201909078T TR 201909078 T4 TR201909078 T4 TR 201909078T4
Authority
TR
Turkey
Prior art keywords
chemical compounds
muscle quality
mammals
quality improvement
pathologies
Prior art date
Application number
TR2019/09078T
Other languages
English (en)
Inventor
Lafont René
Dioh Waly
Raynal Sophie
Veillet Stanislas
Lepifre Franck
Durand Jean-Denis
Original Assignee
Biophytis
Univ Sorbonne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biophytis, Univ Sorbonne filed Critical Biophytis
Publication of TR201909078T4 publication Critical patent/TR201909078T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60F—VEHICLES FOR USE BOTH ON RAIL AND ON ROAD; VEHICLES CAPABLE OF TRAVELLING IN OR ON DIFFERENT MEDIA, e.g. AMPHIBIOUS VEHICLES
    • B60F3/00—Amphibious vehicles, i.e. vehicles capable of travelling both on land and on water; Land vehicles capable of travelling under water
    • B60F3/0007—Arrangement of propulsion or steering means on amphibious vehicles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
    • B63C—LAUNCHING, HAULING-OUT, OR DRY-DOCKING OF VESSELS; LIFE-SAVING IN WATER; EQUIPMENT FOR DWELLING OR WORKING UNDER WATER; MEANS FOR SALVAGING OR SEARCHING FOR UNDERWATER OBJECTS
    • B63C13/00—Equipment forming part of or attachable to vessels facilitating transport over land
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
    • B63B—SHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING 
    • B63B29/00—Accommodation for crew or passengers not otherwise provided for
    • B63B29/02—Cabins or other living spaces; Construction or arrangement thereof
    • B63B2029/022—Bathing platforms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
    • B63H—MARINE PROPULSION OR STEERING
    • B63H11/00—Marine propulsion by water jets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
    • B63H—MARINE PROPULSION OR STEERING
    • B63H25/00—Steering; Slowing-down otherwise than by use of propulsive elements; Dynamic anchoring, i.e. positioning vessels by means of main or auxiliary propulsive elements
    • B63H25/42—Steering or dynamic anchoring by propulsive elements; Steering or dynamic anchoring by propellers used therefor only; Steering or dynamic anchoring by rudders carrying propellers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Combustion & Propulsion (AREA)
  • Ocean & Marine Engineering (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Mevcut buluş, özellikle memelilerde kas kalitesinin iyileştirilmesi için kimyasal bileşikler ve bunların terapötik kullanımları ile ilgilidir. Daha özellikle buluş, sarkopenik memelilerde kas kütlesinin iyileştirilmesine ve sarkopeninin ve özellikle de sarkopenik obezitenin, bunun kuvvet, kas kütlesi, fiziksel performanslar ve kapasite ve hareket kaybı gibi ilişkili komplikasyonları ve/veya patolojilerinin tedavi edilmesi ve/veya önlenmesine olanak sağlamaktadır. Buluş aynı zamanda obez memelilerde kas kalitesinin iyileştirilmesine ve obezitenin ve bunun ilişkili komplikasyonları ve/veya patolojilerinin, avantajlı olması açısından tip 2 diyabet ve metabolik sendromun tedavi edilmesi ve/veya önlenmesine olanak sağlamaktadır.
TR2019/09078T 2014-05-20 2015-05-20 Kimyasal bileşikler ve bunların kas kalitesinin iyileştirilmesine yönelik kullanımı. TR201909078T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1454538A FR3021318B1 (fr) 2014-05-20 2014-05-20 Produits derives de la 20-hydroxyecdysone et leur utilisation dans la preparation de medicaments

Publications (1)

Publication Number Publication Date
TR201909078T4 true TR201909078T4 (tr) 2019-07-22

Family

ID=51518935

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09078T TR201909078T4 (tr) 2014-05-20 2015-05-20 Kimyasal bileşikler ve bunların kas kalitesinin iyileştirilmesine yönelik kullanımı.

Country Status (15)

Country Link
US (2) US9938315B2 (tr)
EP (2) EP3145942B1 (tr)
JP (1) JP6621217B2 (tr)
KR (1) KR102506149B1 (tr)
CN (1) CN106536539B (tr)
AU (1) AU2015263121B2 (tr)
CA (1) CA2949649A1 (tr)
ES (1) ES2732460T3 (tr)
FR (1) FR3021318B1 (tr)
IL (1) IL249062A0 (tr)
PL (1) PL3145942T3 (tr)
PT (1) PT3145942T (tr)
RU (1) RU2724329C2 (tr)
TR (1) TR201909078T4 (tr)
WO (1) WO2015177469A1 (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3065644B1 (fr) * 2017-04-28 2020-02-21 Biophytis Extrait de 20-hydroxyecdysone de qualite pharmaceutique, son utilisation et sa preparation
FR3078252B1 (fr) * 2018-02-28 2020-08-14 Biophytis Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation
FR3093640B1 (fr) 2019-03-15 2021-10-01 Biophytis Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement de maladies neuromusculaires
FR3093641B1 (fr) * 2019-03-15 2023-11-03 Biophytis Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement de l’altération de la fonction respiratoire
FR3108504B1 (fr) * 2020-03-30 2023-03-31 Biophytis Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement d’altérations de la fonction respiratoire lors d’une infection virale
WO2022133265A1 (en) * 2020-12-17 2022-06-23 University Of Florida Research Foundation, Incorported Steroidal compound derivatives as therapeutic agents
FR3128873B1 (fr) 2021-11-10 2026-01-16 Biophytis Phytoecdysones et/ou dérivés de 20-hydroxyecdysone en combinaison avec un principe actif visant à restaurer l’expression SMN pour leur utilisation dans le traitement de l’amyotrophie spinale
FR3143975B1 (fr) 2022-12-23 2025-10-24 Biophytis Phytoecdysones pour leur utilisation dans le traitement de pathologies respiratoires inflammatoires
FR3157102A1 (fr) 2023-12-22 2025-06-27 Biophytis Compositions de phytoecdysones pour leur administration par voie intranasale
FR3158880A1 (fr) 2024-02-01 2025-08-08 Biophytis Phytoecdysones et/ou dérivés de 20-hydroxyecdysone en combinaison avec un agoniste de GLP-1 pour leur utilisation dans le traitement de l’obésité et du surpoids

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618881A1 (en) * 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
EP1996215A2 (en) * 2006-02-28 2008-12-03 Trustees Of Boston University Metabolic regulators and uses thereof
EP2265116A4 (en) 2008-03-14 2013-02-06 Intrexon Corp STEROID LIGANDS AND THEIR USE IN GENE SWITCH MODULATION
FR2982489B1 (fr) 2011-11-10 2013-12-27 Inst Biophytis Sas Phytoecdysones pour leur utilisation dans la stabilisation du poids apres un regime amaigrissant
FR2983733B1 (fr) * 2011-12-13 2017-12-22 Inst Biophytis Sas Phytoecdysones pour leur utilisation dans l'amelioration de la qualite musculaire de mammiferes obeses et/ou sarcopeniques

Also Published As

Publication number Publication date
BR112016027053A8 (pt) 2022-11-29
FR3021318A1 (fr) 2015-11-27
EP3145942A1 (fr) 2017-03-29
JP6621217B2 (ja) 2019-12-18
WO2015177469A1 (fr) 2015-11-26
US9938315B2 (en) 2018-04-10
ES2732460T3 (es) 2019-11-22
EP3461833A1 (fr) 2019-04-03
JP2017516851A (ja) 2017-06-22
AU2015263121B2 (en) 2018-12-06
FR3021318B1 (fr) 2017-04-28
CA2949649A1 (fr) 2015-11-26
KR102506149B1 (ko) 2023-03-07
US20170226151A1 (en) 2017-08-10
US10316056B2 (en) 2019-06-11
PL3145942T3 (pl) 2019-10-31
KR20170027319A (ko) 2017-03-09
IL249062A0 (en) 2017-01-31
BR112016027053A2 (pt) 2017-08-15
RU2016149619A3 (tr) 2018-11-19
CN106536539B (zh) 2020-01-07
EP3145942B1 (fr) 2019-04-03
AU2015263121A1 (en) 2017-01-12
CN106536539A (zh) 2017-03-22
PT3145942T (pt) 2019-07-04
RU2724329C2 (ru) 2020-06-23
RU2016149619A (ru) 2018-06-20
US20180327444A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
TR201909078T4 (tr) Kimyasal bileşikler ve bunların kas kalitesinin iyileştirilmesine yönelik kullanımı.
NZ746950A (en) Heterocyclic gpr119 agonist compounds
ZA201803366B (en) Antibody molecules to april and uses thereof
MX2021015661A (es) Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201990360A1 (ru) Аналоги амилина
AU2017279037A1 (en) New medical use of probiotics
EA201792562A1 (ru) Глюкагон и коагонисты гпп-1
EP3359074A4 (en) ELECTROPORATION FOR THE TREATMENT OF ADIPOSITAS OR DIABETES
PH12019500254A1 (en) Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
MX2017012864A (es) Analogo acilado del glucagon.
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA201791712A1 (ru) Антитела к транстиретину
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
BR112017008045A2 (pt) compostos como inibidores de nik
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
NZ738100A (en) Igfbp3 and uses thereof
WO2015168602A3 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
GB201707207D0 (en) Treatment of type 1 diabetes
MX2015008555A (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
AU2017261919A1 (en) Fat and medical uses thereof
SG11201704840RA (en) Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes
PH12020500339A1 (en) Novel compounds
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета